Susan Lorentzen et al v. Pfizer, Inc. et al
ORDER by Judge Cormac J. Carney remanding case to Superior Court of CAlifornia, County of Los Angeles, Case number BC 677995. (see document for details). Case Terminated. Made JS-6 (dro)
UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
CIVIL MINUTES – GENERAL
Case No. CV 17-08618-CJC(JPRx)
Date: November 30, 2017
Title: SUSAN LORENTZEN ET AL. V. PFIZER, INC. ET AL.
HONORABLE CORMAC J. CARNEY, UNITED STATES DISTRICT JUDGE
ATTORNEYS PRESENT FOR PLAINTIFF:
ATTORNEYS PRESENT FOR DEFENDANT:
PROCEEDINGS: (IN CHAMBERS) ORDER REMANDING CASE
Thousands of women filed over 100 cases in California state court alleging that
Lipitor, a prescription drug developed and manufactured by Pfizer and marketed and
distributed by McKesson Corporation, had caused them to suffer from Type II diabetes.
The cases were removed to federal court based on “mass action” jurisdiction pursuant to
the Class Action Fairness Act (“CAFA”), referred to the United States Judicial Panel of
Multidistrict Litigation (“MDL”), subsequently sent back to this Court, and then
consolidated under a master case number for administrative purposes (the “17-00005
Case”). (SAMC 17-00005-CJC(JPRx).) On May 23, 2017, the Court remanded the cases
to state court, finding the requirements of CAFA mass action jurisdiction were not met.
(SAMC 17-00005-CJC(JPRx) Dkt. 20.)
This action was initiated after the Court issued its remand order, so it was not
consolidated under the 17-00005 Case. This case is REMANDED to state court for the
reasons articulated in the Court’s orders dated May 23, 2017, and May 31, 2017, in the
17-00005 Case. (SAMC 17-00005-CJC(JPRx) Dkts. 20, 24.)
MINUTES FORM 11
Initials of Deputy Clerk MKU
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?